Clinical Trial

Antibiotic Therapy in Viral Airway Infections

Study acronym: ATHENIAN
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Antimicrobial resistance is one of the most urgent health threats of our time, and Norwegian hospitals were required to reduce the use of broad-spectrum antibiotics with 30% by the end of 2020. In the current proposal, the investigators aim to assess the efficacy and safety of early discontinuation of antibiotic therapy in adult patients infected with respiratory viruses. A general recommendation to treat all instances of community acquired pneumonia (CAP) patients with antibiotics leads to significant antibiotic overtreatment. In 2008, the US Food and Drug Administration approved the first multiplex polymerase chain reaction assay for the detection of multiple respiratory virus nucleic acids simultaneously. The wide availability of such nucleic acid amplification tests (NAAT) for rapid viral detection together with chest radiographs has the potential to define patients who can be managed without antibiotics. Akershus University Hospital is one of the largest hospitals in Norway, with a catchment area of more than 550,000 people. In 2012 to 2013, the majority of patients admitted to Akershus University Hospital with suspected CAP and a positive viral NAAT were treated with antibiotics, a prescription pattern representing antibiotic overtreatment. The investigators accordingly hypothesize that discontinuation of antibiotic therapy in patients with moderately severe disease and airway sample positive for respiratory viruses is safe and non-inferior to continuation of antibiotic therapy.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2021-09-07; most recent amendment 2025-08-11.
Status change: Not Yet Recruiting → Recruiting 2022-02-14
Trial Details
NCT Number NCT05045612
Lead Sponsor University Hospital, Akershus
Collaborators: University of Oslo
Conditions Infectious Disease, Influenza, Respiratory Syncytial Virus (RSV), Respiratory Tract Infections
Enrollment 380 participants
Start Date 2022-01-13
Primary Completion 2027-05 (estimated)
Study Completion 2029-11 (estimated)
Updated on ClinicalTrials.gov 2025-08-12